A Comparison of Bleomycin/Vincristine versus Vincristine Monotherapy on the Probability of Tumor Improvement at 40–42 Weeks*.

*Comparison of the probability of tumor improvement versus tumor non-improvement among patients on Bleomycin/Vincristine versus those on Vincristine monotherapy. In model (A), only patients with recorded tumor information are included. In model (B), all patients who were dead or lost/defaulted were also included and categorized with tumor non-improvement. In model C, all patients who were dead, lost/defaulted, or missing were classified as having tumor non-improvement. All adjusted models control for age and baseline CD4 count.